Publication | Open Access

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

First-line TherapyBreast OncologyMedicinePharmacologyClinical TrialsPaclitaxel Versus PlaceboBreast CancerPharmacotherapyCancer TreatmentOncology